Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Status:
Terminated
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
Two randomized trials in the cytokine era clearly showed that cytoreductive nephrectomy (CN)
had a role in metastatic renal cell carcinoma (mRCC) increasing life expectancy. The survival
benefit of tyrosine kinase inhibitors (TKIs) including first-line sunitinib and pazopanib in
mRCC has been demonstrated, but the majority of patients enrolled in the pivotal phase III
studies had undergone nephrectomy.
Therefore it is unknown if similar survival benefit could be achieved without CN with these
new targeted agents.
At the same time there is a need to better understand mechanisms of primary and secondary
resistance to TKIs in mRCC patients and to identify eighter prognostic and predictive
biomarkers to better define risk factors and potentially druggable targets.
Phase:
Phase 3
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano